PDCD1 and neoplasm: The combined administration of anti-PD-1/PD-L1 and anti-LAG-3 antibodies displays a synergistic ability to inhibit tumor growth, as evidenced in phase 2/3 trials where the combination of relatlimab and nivolumab yielded significantly prolonged PFS compared to nivolumab alone [123–125].